<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105698</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GLCL003</org_study_id>
    <nct_id>NCT05105698</nct_id>
  </id_info>
  <brief_title>Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg</brief_title>
  <official_title>Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet Under Fed and Fasting Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open-label, Single-dose, Two-way Crossover Study to Investigate Food-effect&#xD;
      Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated&#xD;
      Tablet under Fed and Fasting Conditions in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Objectives]&#xD;
&#xD;
        -  Primary: To investigate the food-effect bioavailability of absorption of gemigliptin and&#xD;
           dapagliflozin 50/10 mg fixed dose combination film-coated tablet in healthy subjects&#xD;
           under fed and fasting conditions&#xD;
&#xD;
        -  Secondary: To evaluate safety of investigational product under fed and fasting&#xD;
           conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00</time_frame>
    <description>Cmax will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentrationup up to the last measurable concentration (AUC0-tlast)</measure>
    <time_frame>Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00</time_frame>
    <description>AUC0-tlast will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve to from time 0 to infinite(AUC0-∞)</measure>
    <time_frame>Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00</time_frame>
    <description>AUC0-∞ will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>fasting conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once without food (fasting conditions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fed conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once with food (fed conditions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)</intervention_name>
    <description>Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)</description>
    <arm_group_label>fasting conditions</arm_group_label>
    <other_name>DPP-4 inhibitor and SGLT-2 inhibitor combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)</intervention_name>
    <description>Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)</description>
    <arm_group_label>fed conditions</arm_group_label>
    <other_name>DPP-4 inhibitor and SGLT-2 inhibitor combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female, healthy volunteers aged 18-55 years, body mass index between 18.0 to&#xD;
             30.0 kg/m2. All of them should be able to complete the clinical study including the&#xD;
             follow-up and capable of providing written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History serious hypersensitivity reactions&#xD;
&#xD;
          -  History or evidence of clinically significant renal, hepatic, gastrointestinal&#xD;
&#xD;
          -  Have high risk for coronavirus infection based on risk assessment questionnaire or&#xD;
             diagnosed as confirmed case of COVID-19&#xD;
&#xD;
          -  History about administration of first dose or second dose of COVID-19 vaccine within&#xD;
             30 days prior to check-in in each Period&#xD;
&#xD;
          -  History or evidence of family diabetes&#xD;
&#xD;
          -  History or evidence of type 1 diabetes mellitus, diabetic ketoacidosis, diabetic&#xD;
             pre-coma&#xD;
&#xD;
          -  etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>eunjoo cho</last_name>
    <phone>+82-2-6987-4284</phone>
    <email>eunjoo.cho@lgchem.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

